Overview
Portfolio
More
ATEM Capital
New York, United States
ATEM Capital focuses on life‑science innovations, investing from pre‑seed through later‑stage rounds in biotech, digital health and AI‑driven drug discovery. It targets companies addressing unmet clinical needs in rare d...
Portfolio
10+
Employees
5+
Founded
N/A
AUM
≈ $0.0
Investment focus
Stages
Stage agnostic
Industries
Artificial IntelligenceBiotechnologyDigital Health
Geographic scope
EuropeUnited States
Fund details
Check sizes
Min: $20.0M
Typical: $138.0M
Max: $138.0M
Sources
ATEM Capital
ATEM Capital focuses on life‑science innovations, investing from pre‑seed through later‑stage rounds in biotech, digital health and AI‑driven drug discovery. It targets companies addressing unmet clinical needs in rare diseases, oncology and digital therapeutics, leveraging strong IP and strategic partnerships. The firm collaborates with US and Western European venture partners to generate high‑return, high‑impact healthcare breakthroughs.
Portfolio
10+
Employees
5+
Founded
N/A
AUM
≈ $0.0
Check Sizes
Min: $20.0M
Typical: $138.0M
Max: $138.0M
Stages
Stage agnostic
Industries
Artificial IntelligenceBiotechnologyDigital Health
Geographic scope
EuropeUnited States
Sources
Showing 8 of 8 matched portfolio companies
Develops a high-throughput transcriptomic sequencing platform that generates chemotranscriptomes to map chemical interactions to biological networks. This technology enables the discovery of potential drugs targeting chronic diseases, including cancer, chronic kidney disease, and neurodegeneration, by addressing challenges like drug resistance.
Funding: $20.4M
Rough estimate of the amount of funding raised
Funding: $20.4M
Rough estimate of the amount of funding raised
Atea Pharmaceuticals is developing oral direct-acting antiviral therapies, specifically bemnifosbuvir and ruzasvir, for the treatment of hepatitis C virus (HCV) and COVID-19. The company targets the unmet medical need for effective antiviral treatments, as millions of HCV patients remain untreated despite the availability of therapies.
Funding: $215.0M
Rough estimate of the amount of funding raised
Funding: $215.0M
Rough estimate of the amount of funding raised
Develops personalized cytokine-based therapies using a proprietary Diakine™ platform that combines anti-inflammatory and immune-stimulating cytokines to target cancer and inflammatory diseases. This approach enriches affected tissues with tailored cytokine combinations, aiming to control disease while minimizing toxic inflammation, offering a precision medicine solution for individual patient immune responses.
Funding: $90.9M
Rough estimate of the amount of funding raised
Funding: $90.9M
Rough estimate of the amount of funding raised
Iridia utilizes Molecular Avatar Technology to embed unalterable molecular identities into products, ensuring authenticity and traceability without altering their appearance or functionality. This technology addresses counterfeiting and enhances supply chain visibility across various industries, including luxury retail and aerospace.
Funding: $31.8M
Rough estimate of the amount of funding raised
Funding: $31.8M
Rough estimate of the amount of funding raised
Marius Pharmaceuticals develops KYZATREX, an oral testosterone undecanoate therapy absorbed primarily via the lymphatic system, designed to treat adult men with hypogonadism, a condition characterized by low testosterone levels. This therapy addresses the significant health impacts of testosterone deficiency, including fatigue, decreased libido, and increased risk of metabolic disorders, by restoring testosterone levels to the normal range in a majority of patients.
Funding: $6.0M
Rough estimate of the amount of funding raised
Funding: $6.0M
Rough estimate of the amount of funding raised
Pria is a HIPAA-compliant technology platform that integrates remote care solutions for chronic condition management, enabling healthcare organizations to deliver these services at scale. By improving patient engagement and adherence, Pria addresses the inefficiencies in remote care that lead to significant healthcare costs and poor health outcomes.
Triumvira Immunologics develops T cell therapies using its proprietary T cell Antigen Coupler (TAC) platform, which enhances T cell activation to target and destroy cancer cells across various tumor types. This approach addresses the challenge of treating difficult-to-manage cancers by leveraging the body's natural immune response for improved therapeutic outcomes.
Funding: $168.0M
Rough estimate of the amount of funding raised
Funding: $168.0M
Rough estimate of the amount of funding raised
Walden Biosciences is developing targeted gene editing therapies to modify renal cell function in patients with chronic kidney disease. This approach aims to improve patient outcomes by reducing reliance on dialysis and kidney transplants.
Funding: $51.0M
Rough estimate of the amount of funding raised
Funding: $51.0M
Rough estimate of the amount of funding raised
Showing 2 of 2 unmatched portfolio companies